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Abstract 
The carotid body (CB) is the main peripheral chemoreceptor that senses the arterial PO2, PCO2 and pH. In response 
to hypoxemia, hypercapnia and acidosis, carotid chemosensory discharge elicits reflex respiratory, autonomic and 
cardiovascular adjustments. The classical construct considers the CB as the main peripheral oxygen sensor, triggering 
reflex physiological responses to acute hypoxemia and facilitating the ventilatory acclimation to chronic hypoxemia 
at high altitude. However, a growing body of experimental evidence supports the novel concept that an abnormally 
enhanced CB chemosensory input to the brainstem contributes to overactivation of the sympathetic nervous system, 
and consequent pathology. Indeed, the CB has been implicated in several diseases associated with increases in 
central sympathetic outflow. These include hypertension, heart failure, sleep apnea, chronic obstructive pulmonary 
disease and metabolic syndrome. Indeed, ablation of the CB has been proposed for the treatment of severe and 
resistant hypertension in humans. In this review, we will analyze and discuss new evidence supporting an important 
role for the CB chemoreceptor in the progression of autonomic and cardiorespiratory alterations induced by heart 
failure, obstructive sleep apnea, chronic obstructive pulmonary disease and metabolic syndrome.
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Background 
The carotid body (CB) is a polymodal chemoreceptor 
located in the carotid bifurcation, which is activated by 
hypoxemia, hypercapnia, acidosis, reduction of arte-
rial blood flow, temperature change and low levels of 
glucose [1–4]. Reflex cardiorespiratory responses are 
characterized by hyperventilation and increased sym-
pathetic discharge to the vascular beds and the heart. 
Tachycardia associated with hyperventilation in turn 
augments cardiac output, acutely raising arterial blood 
pressure. The CB chemoreceptor (glomus or type I) 
cells, which make synaptic contact with the nerve ter-
minals of the chemosensory petrosal neurons, are 
considered the sensors of the natural stimuli [1–4]. 
The current model of CB chemoreception holds that 
hypoxia and hypercapnia-acidosis close voltage inde-
pendent (TASK) and voltage-dependent K+ channels, 
leading to glomus cell depolarization, entry of Ca2+ 
through L-type Ca2+ channels, and release of one or 
more excitatory transmitters, which increases the dis-
charges of the nerve endings of chemosensory neurons 
[2–5]. Several molecules are present in glomus cells, but 
acetylcholine and adenosine triphosphate fulfill most of 
the criteria to be considered as excitatory transmitters 
between the glomus cells and petrosal nerve endings 
[3–5]. However, other molecules such as dopamine, his-
tamine, nitric oxide (NO), carbon monoxide, H2S, and 
endothelin-1 (ET-1) modulate the chemosensory pro-
cess by producing tonic actions on CB blood vessels or 
direct effects on glomus cells [3–5]. More recently, pro-
inflammatory cytokines such as interleukin 1β, inter-
leukin 6 and TNF-α have been found to modulate CB 
chemoreception in rats [6–8].
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The classical physiological paradigm considers the 
CB as the main oxygen sensor, triggering ventilatory 
responses to acute hypoxemia and modulating the ven-
tilatory acclimation to high altitude. Notwithstanding, 
a growing body of evidence involved the CB in several 
sympathetic-mediated human diseases [8–17]. Indeed, 
selective ablation of the CB improves survival in heart 
failure (HF) experimental models [10, 11], prevents the 
development of insulin resistance and hypertension 
in rats fed with a high fat diet [18], and attenuates the 
hypertension induced by chronic intermittent hypoxia in 
a rat model of obstructive sleep apnea [19].
The carotid body and heart failure
Heart failure (HF) is characterized by frequent hospi-
talizations and high mortality risk. Accordingly, HF is 
considered a major health problem, affecting 20 % of the 
adult population [20, 21]. The pathophysiology of HF is 
characterized by a progressive decrease in cardiac func-
tion, which severely impacts the blood supply to several 
vascular beds [22–24]. Two main characteristics of HF 
are the presence of autonomic imbalance and disordered 
breathing patterns, both of which has been shown to be 
strongly associated with the degree of cardiac failure 
[11, 25–27]. Indeed, the contribution of heightened CB 
chemoreflex drive and excessive sympathetic outflow to 
the development and progression of HF has been demon-
strated in both humans and experimental animal models 
[13, 27, 28]. Indeed, an enhanced CB chemoreflex drive 
has been shown to play a key role in the progression of 
cardiorespiratory disorders in HF [11, 29], and high CB 
chemosensitivity correlates strongly with high mortal-
ity risk and poor prognosis in patients with HF [30]. In 
experimental HF, the CB chemosensory activity is toni-
cally elevated leading to sympatho-excitation and desta-
bilization of breathing [13, 27, 31].
The physiological mechanisms underlying cardiores-
piratory alterations in HF are not fully understood. The 
most widely accepted model of CB chemoreflex regula-
tion states that chemosensory nerve fibers from the CB 
project to the nucleus tractus solitarius (NTS), which 
integrates the CB afferent visceral sensory input. The 
NTS in turn sends efferent projections to the respiratory 
neuronal network and brainstem autonomic sympathetic 
nuclei, such as the rostral ventrolateral medulla (RVLM) 
[32]. It has been shown that in HF rats, the CB chem-
osensory discharge in normoxia is enhanced resulting 
in hyper-activation of pre-sympathetic neurons located 
in the RVLM, which finally leads to increased central 
sympathetic outflow [33]. Furthermore, Marcus et  al. 
[27] showed that an augmented CB afferent activity trig-
gered respiratory-sympathetic coupling in rabbits with 
HF. Notably, selective ablation of the CB chemorecep-
tors decreased RVLM pre-sympathetic neuron activa-
tion, restored normal sympathetic outflow, and markedly 
reduced the incidence of oscillatory breathing patterns 
in HF (see Fig.  1). Additionally, if performed early dur-
ing the progression of HF, CB ablation reduced collagen 
deposition and fibrosis in the ventricular myocardium, 
decreased the number of cardiac arrhythmias, blunted 
cardiac function deterioration and strikingly improved 
survival of HF rats (Fig.  2). Together, these results 
strongly support a crucial role of the CB in the develop-
ment of abnormal breathing patterns and increased sym-
pathetic outflow, adding more stress to the failing heart, 
and ultimately leading to higher mortality risk.
The tonic hyper-activation of the CB chemoreceptor 
cells during HF appears to be a key step in disease pro-
gression. Identifying molecular mechanisms underly-
ing CB chemoreceptor activation could therefore lead 
to novel future interventions intended to normalize CB 
chemosensory activity in HF. Recently, Schultz and col-
leagues provided a comprehensive review on the plausi-
ble mechanisms underpinning the enhanced CB function 
in HF [34]. Due to the nature of HF, a chronic reduction 
in blood supply to several organs is expected during the 
progression of the disease. Thus, it has been hypothesized 
that blood flow restrictions to the CB region could play a 
role in inducing augmented CB chemosensory discharge 
in HF. Ding et  al. [35] provide the first evidence show-
ing that chronic blood flow restrictions to the CB in nor-
mal animals induced CB chemorelfex activation. Indeed, 
reducing blood supply to the CB to a similar extent to 
flows observed in HF animals results in CB chemosensory 
potentiation and increases in renal sympathetic nerve 
activity [35]. Recently, the blood flow-sensitive transcrip-
tion factor, Kruppel-like factor 2 (KLF-2), was shown to be 
constitutively expressed in the CB, particularly in chemo-
receptor cells [36]. Furthermore, KLF-2 expression in the 
CBs is markedly reduced during HF [36]. The viral trans-
duction of KLF-2 in the CB of rabbits with HF normalizes 
CB function and reduces sympathetic outflow despite the 
chronic reduction of blood flow to the tissue [34]. In addi-
tion, other factors such as decreases in NO bioavailability 
and increases in local and systemic levels of angiotensin 
II also could contribute to an increased CB chemore-
flex drive in HF. Furthermore, oxidative stress has been 
related to augmented CB discharge in HF, since genetic 
manipulation to increase superoxide dismutase within the 
CB tissue significantly reduced CB afferent activity [35]. 
Further studies are needed to uncover the role played by 
KLF-2 in the regulation of NO synthase expression as well 
as superoxide dismutase expression and local angiotensin 
II production in the CB during HF.
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The carotid body and obstructive sleep apnea
Obstructive sleep apnea (OSA) is elicited by repeated 
total or partial occlusions of the upper airway, and is 
associated with daytime sleepiness, fatigue, depressed 
mood, and cognitive alterations [37, 38]. Several epi-
demiological studies have demonstrated that OSA is an 
Fig. 1 Carotid body mediates sympathoexcitation and oscillatory breathing patterns in heart failure. Representative recordings of tidal ventila-
tion (Vt), renal sympathetic nerve activity (RSNA) and integrated RSNA (iSNA) in one control (sham–sham) animal, one chronic heart failure animal 
with intact carotid bodies (CHF–sham) and one chronic heart failure animal that underwent carotid body denervation (CHF–CBD). Note that CBD 
normalize RSNA and ventilatory oscillations. Reprinted from Marcus et al. [27] with permission of John Wiley and Sons
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independent risk factor for the development and pro-
gression of systemic hypertension, showing a positive 
correlation between the apnea/hypopnea index and the 
severity of hypertension [38–41]. The repeated episodes 
of airflow obstruction during sleep produces cyclic inter-
mittent hypoxemia and hypercapnia, which stimulate the 
CB eliciting reflex ventilatory, sympathetic and hyperten-
sive responses. Among these disturbances, chronic inter-
mittent hypoxemia (CIH) is considered the main factor 
related to systemic hypertension [17, 42–48].
Although the link between OSA and hypertension is 
well established, the pathogenic mechanisms underly-
ing the onset and maintenance of the hypertension are 
not entirely known. It has been proposed that CIH elicits 
oxidative stress, inflammation, and sympathetic hyperac-
tivity, which leads to endothelial dysfunction and hyper-
tension [8, 17, 43, 49, 50]. However, studies performed in 
OSA patients are limited by degree of invasiveness, and 
because OSA patients often present concomitant co-
morbidities (such as obesity and metabolic alterations), 
which themselves increase cardiovascular risk. Therefore, 
casual relationships between OSA and associated disease 
conditions are not well demarcated. On the other hand, 
experimental models of rodents exposed to CIH repro-
duce several cardiovascular pathologic features of OSA 
including hypertension and sympathetic hyperactivity [8, 
19, 51–54, 56–62].
Patients with recently diagnosed OSA show enhanced 
vasopressor and ventilatory responses to acute hypox-
emia [63–66], and manifest sympathetic hyperactivity 
evidenced by an increased muscle sympathetic neural 
activity [67] and higher levels of urinary norepinephrine 
[68]. Similarly, rodents exposed to CIH have enhanced 
cardiorespiratory and sympathetic responses to hypoxia, 
and develop systemic hypertension [5, 69–74]. Further-
more, both OSA patients and animals exposed to CIH 
show reduction of baroreflex gain and alterations of heart 
rate variability towards a predominance of sympathetic 
drive [51, 65, 75–79]. Thus, it is likely that enhanced sym-
pathetic activity along with reduction of baroreflex gain 
may contribute to the rise of arterial blood pressure fol-
lowing CIH. The enhanced cardiorespiratory responses 
to acute hypoxemia found in patients with recently diag-
nosed OSA has been attributed to an enhanced hypoxic 
chemoreflex [63–66, 80], suggesting that the CB is 
involved in the pathological alterations induced by OSA. 
Fig. 2 Carotid Body denervation reduced myocardial fibrosis and cardiac arrhythmias and improved survival in heart failure rats. a Rats with chronic 
heart failure (CHF) and with CHF and carotid body denervation (eCBD) displayed tissue fibrosis in noninfarcted areas. The left ventricle (LV) freewall 
and the interventricular septum (IVS) obtained from CHF rats showed a marked collagen deposition. Selective eCBD significantly reduced cardiac 
fibrosis in the LV-freewall and in the IVS. b Representative tachograms showing arrhythmic episodes in a CHF rat and a marked decreased in the 
arrhythmic events in CHF+eCBD rat. c Rats that underwent eCBD showed reduced mortality rate compared to CHF rats with functional CBs. Modi-
fied from Del Rio et al. [10], with permission of Elsevier
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Although Fletcher et  al. [19] found that CB denerva-
tion prevented hypertension in rats exposed to CIH, the 
contribution of the CB to the cardiovascular pathology 
induced by OSA was not considered. However, in the 
last decade the proposal that an abnormally enhanced 
CB chemosensory drive is involved in the progression 
of CIH-induced hypertension has received substantial 
attention [43, 49, 58, 81]. Recordings of CB neural dis-
charges in  situ and in  vitro have demonstrate that CIH 
selectively increases basal discharge in normoxia, and 
potentiates the chemosensory responses to acute hypoxia 
[18, 51, 52, 54–59, 78, 79] (see Fig. 3).
Reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) have been implicated as mediators of car-
diovascular and cognitive alterations in OSA patients 
[44, 82–85] and animal models [51, 52, 54, 55, 57, 59]. 
We tested the hypothesis that oxidative stress contrib-
utes to CB chemosensory potentiation and the progres-
sion of the hypertension in rats exposed to CIH [51]. 
We found that CIH increased plasma lipid peroxidation 
and formation of the oxidative stress marker 3-nitroty-
rosine (3-NT) in the CB. In addition, CIH enhanced CB 
chemosensory and ventilatory responses to hypoxia and 
elicited hypertension. Antioxidant treatment with ascor-
bic acid reduced the increased systemic and CB oxida-
tive stress, normalized CB chemoreflex function, and 
markedly reduced the elevated arterial blood pressure. 
Although, these results strongly suggest that CB chem-
osensory potentiation is mediated by oxidative stress, it is 
a matter of debate as to whether ROS per se may increase 
CB chemosensory discharge [86]. Thus, it is likely that 
other molecules downstream of ROS signaling mediate 
the CIH-induced effects of ROS on CB chemoreception. 
Among the molecules upregulated in the CB by CIH, 
such as ET-1, VEGF and iNOS [52, 53, 79, 87, 89], pro-
inflammatory cytokines have been proposed as mediators 
of the CB chemosensory potentiation induced by CIH [8, 
9, 52, 54, 87, 88, 89]. We found that CIH induced a ROS-
dependent increase in TNF-α and IL-1β levels in the CB, 
suggesting that these pro-inflammatory cytokines may 
mediate the ROS-induced CB potentiation [51, 52]. Fur-
thermore, ibuprofen treatment prevented CB cytokine 
overexpression, as well as the enhanced hypoxic ventila-
tory response and the hypertension, but failed to block 
the enhanced CB chemosensory responses [54]. Thus, 
our studies suggest that upregulation of TNF-α and IL-1β 
in the CB induced by CIH is linked to oxidative stress, as 
well as to the enhanced CB chemosensory responsive-
ness to hypoxia, but the chemosensory potentiation does 
not depend on the increased TNF-α and IL-1β levels in 
the CB. However, pro-inflammatory cytokines contrib-
ute to enhance the hypoxic ventilatory response and to 
the hypertension induced by CIH, suggesting that multi-
ple mechanisms may participate in the cardiorespiratory 
alterations induced by CIH.
The carotid body and chronic obstructive 
pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a sys-
temic disease that includes many extra pulmonary mani-
festations including systemic inflammation, cachexia, 
and muscle dysfunction [90]. Increased sympathetic acti-
vation in COPD is evident from increased plasma nor-
epinephrine, and associated with increased plasma renin 
activity and aldosterone concentration [90]. Heightened 
muscle sympathetic nerve activity occurs in patients with 
chronic respiratory failure [91–93]. In COPD patients, 
coexistent hypoxemia and hypercapnia, activates 
peripheral chemoreceptors (hypoxemia) and central 
chemoreceptors (hypercapnia). Short-term oxygen sup-
plementation reduces muscle sympathetic nerve traffic 
in these patients [91] suggesting that peripheral chemo-
receptors are involved. Sympathetic activation in COPD 
may be also related to other conditions like arterial 
and cardiac baroreflex dysfunction, breathing patterns 
Fig. 3 CIH increased basal carotid chemosensory discharges 
and induced a potentiation of chemosensory responses to acute 
hypoxia. The chemosensory responses to various levels of inspired 
O2 (PO2 ≈ 100−1 %) were measured from one carotid sinus nerve 
of a sham rat (a) and from a rat exposed to cyclic hypoxic episodes 
(PO2 to 35 mmHg, 12 times per h during 8 h) for 21 days. (b) ƒcsn, 
frequency of carotid chemosensory discharges expressed in Hz. Rats 
were anesthetized with sodium pentobarbitone (40 mg/kg ip) and 
breathed spontaneously room air. Reprinted from Iturriaga et al. [8] 
with permission of John Wiley and Sons
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and metaboreflex excitation [94]. Indeed, slow breath-
ing causes a drop of sympathetic overactivity in COPD 
[95], possibly improving baroreflex sensitivity and gas 
exchange. The peripheral chemoreceptors therefore are 
likely contributors to elevated muscle sympathetic nerve 
discharge in COPD [92].
Metabolic alterations: a new role for the carotid 
body?
Metabolic syndrome is a growing health problem world-
wide, with a high prevalence and strong associations with 
cardiovascular risk and diabetes. Autonomic dysfunction, 
characterized by sympathetic hyperactivity, vagal impair-
ment, and impaired baroreflex sensitivity are characteris-
tics of the metabolic syndrome and of disease conditions 
where the CB may be implicated, such as hypertension 
[96–99]. In addition, patients with metabolic disorders 
also have increased levels of leptin, ROS and pro-inflam-
matory cytokines. It is conceivable that CB chemosen-
sory function may be compromised in the metabolic 
syndrome. In fact, it is known that obesity increases 
adipokine levels (i.e. leptin, resistin, TNF-α and IL-6), 
which in turn may activate NADPH oxidase increasing 
superoxide radical production. Superoxide reacts with 
NO to form peroxynitrite, decreasing NO availability, 
which contributes to the endothelial dysfunction [100]. 
We found a marked increase of 3-NT in the CB from rats 
exposed to CIH, which correlates with the enhanced che-
mosensory responses to hypoxia [51, 52], supporting the 
idea that oxidative-nitrosative stress plays a critical role 
in CB chemosensory potentiation induced by CIH [8, 9, 
52, 53].
The notion that the CB is involved in the metabolic 
regulation of glucose and insulin is not new [12, 101]. 
Recently, Ribeiro et al. [18] studied the role played by the 
CB in a rat model of insulin resistance induced by high fat-
sucrose diets. They found that CB stimulation by insulin 
seems to be involved in the development of insulin resist-
ance and hypertension. Bilateral CB denervation prevents 
diet-induced insulin resistance and hypertension, suggest-
ing that insulin-induced CB chemosensory excitation is 
responsible for the increased sympathetic outflow, cre-
ating a positive feedback, which results in severe insulin 
resistance and hypertension. Furthermore, Porzionato 
et  al. [14] suggested that the CB chemoreceptors are a 
link between the metabolic disorders and the effects of 
CIH. Indeed, they proposed that “hyperleptinemia and 
CIH may be interrelated mechanisms of sympathoacti-
vation through peripheral chemoreceptors, because CIH 
increases plasma leptin levels and leptin immunoreactiv-
ity in the CB”. Recently, Trombetta el al. [102] found evi-
dence that metabolic disorders may interact with OSA to 
potentiate the hypoxic chemoreflexes in humans. In fact, 
they reported that OSA patients with metabolic syndrome 
had a higher ventilatory response to hypoxia, and higher 
muscle sympathetic basal discharge in normoxia and in 
response to hypoxia, than OSA patients without a meta-
bolic disorder, suggesting that metabolic syndrome could 
enhanced the CB chemoreflex drive. Similarly, Fenik et al. 
[103] found that rats exposed to CIH for 35 days showed 
progressively reduced responses to insulin, which dis-
appeared after 35  days of normoxic exposure. They also 
found that treatment with losartan eliminated the effects 
of CIH on insulin release, suggesting a role for the angi-
otensin-catecholaminergic pathway. Although these new 
and provocative ideas suggest that metabolic alterations 
may enhance CB chemosensory responses to hypoxia and 
increase sympathetic outflow, direct recordings of CB 
chemosensory discharge in metabolically altered mod-
els are required to determine if metabolic alterations in 
and of themselves, do indeed increase CB chemosensory 
activity.
Conclusions
In summary, the available evidence suggests that the CB 
contributes to the development of autonomic alterations. 
Identification of those pathways underlying the contri-
bution of the CB to hypertension induced by CIH will 
provide new insights into the pathogenesis of the cardio-
vascular alterations observed in OSA and other disease 
conditions. Furthermore, a mechanistic understanding 
of altered CB function in sympathetic-mediated diseases 
will be relevant to improve current treatment options and 
to develop new therapeutic strategies intended to reduce 
human disease progression.
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